New drug combo shows promise for Hard-to-Treat cancers
Disease control
ENROLLING_BY_INVITATION
This study tests a new drug called RNDO-564, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like lung, bladder, or breast cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if t…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC